TOPLINE:
In clients with type 2 diabetes, there was no distinction in threat of establishing autoimmune illness if recommended glucagon-like peptide 1 receptor agonists (GLP-1-RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors.
METHOD:
- The impact of GLP-1-RAs and SGLT2 inhibitors on autoimmune rheumatic illness (ARD) is understudied, though previous case reports and one research study have actually meant increased threat.
- Scientists utilized administrative health information from 2014 to 2021 to determine 34,400 clients recommended GLP-1-RAs and 83,500 clients recommended SGLT2 inhibitors.
- They compared clients recommended GLP-1-RAs or SGLT2 inhibitors with 68,400 clients recommended DPP-4 inhibitors, which previous research studies recommend do not increase ARD threat.
- Main result was ARD occurrence, specified by diagnostic codes.
TAKEAWAY:
- There were no considerable distinctions in occurrence ARDs in between the 3 groups.
- Mean follow-up time was 0.88-1.53 years.
- The risk ratio (HR) for establishing ARDs with GLP-1-RAs direct exposure was 0.93 (95% CI, 0.66-1.30) compared to DPP-4 inhibitors.
- The HR for establishing ARDs with SGLT2 inhibitor direct exposure was 0.97 (95% CI, 0.76-1.24).
IN PRACTICE:
“Extended longitudinal information are required to evaluate threat and advantage with longer-term direct exposure,” the authors composed.
SOURCE:
Author Derin Karacabeyli, MD, of the University of British Columbia, Vancouver, Canada, provided the research study in abstract kind at the Canadian Rheumatology Association (CRA) 2024 Annual Meeting in Winnipeg on February 29.
CONSTRAINTS:
The research study was observational, which might have some recurring or unmeasured confounding of information. The scientists depend on diagnostic codes and the typical follow-up time was brief.
DISCLOSURES:
The research study was moneyed by the Canadian Institutes of Health Research. The authors had no disclosures.
